Drug updated on 11/14/2023
|Injection (intravenous: 400 mg lyophilized powder )
|Zaire ebolavirus glycoprotein directed human monoclonal antibodies
| Ongoing and
- For the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Product Monograph / Prescribing Information
|Ebanga (ansuvimab-zykl) Prescribing Information.
|Ridgeback Biotherapeutics, LP, Miami, FL
Systematic Reviews / Meta-Analyses
|A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020.
|Journal of Infection and Public Health